MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.3 USD | -0.74% |
|
-1.47% | +17.83% |
| 02:36pm | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
| 13/05 | Merck: phase 3 trial in melanoma halted | CF |
ETFs positioned on Merck & Co., Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.04% | 1,174 M€ | +23.54% | ||
| 1.04% | 655 M€ | -.--% | - | |
| 1.04% | 273 M€ | -.--% | ||
| 1.02% | 559 M€ | +14.30% | ||
| 1.02% | 1,848 M€ | +18.39% | - | |
| 1.01% | 2,383 M€ | +12.53% | ||
| 0.93% | 104 M€ | +8.89% | ||
| 0.93% | 1,006 M€ | -.--% | - | |
| 0.93% | 414 M€ | +11.88% | - | |
| 0.88% | 6 M€ | +17.98% | - | |
| 0.88% | 26 M€ | +19.98% | - | |
| 0.87% | 121 M€ | +6.82% | - | |
| 0.87% | 29 M€ | -.--% | - | |
| 0.87% | 322 M€ | +13.88% | - | |
| 0.80% | 1,083 M€ | +3.88% | ||
| 0.78% | 265 M€ | +5.17% | - | |
| 0.71% | 2 M€ | +21.73% | - | |
| 0.71% | 8 M€ | +5.74% | - | |
| 0.71% | 744 M€ | +8.55% | ||
| 0.70% | 284 M€ | -.--% | ||
| 0.70% | 1 M€ | -.--% | ||
| 0.70% | 264 M€ | -.--% | - | |
| 0.70% | 34 M€ | +11.62% | - | |
| 0.70% | 187 M€ | +9.40% | - | |
| 0.69% | 477 M€ | +11.41% | ||
| 0.68% | 23 M€ | -.--% | - | |
| 0.68% | 786 M€ | -.--% | ||
| 0.68% | 22 M€ | +14.86% |
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.3
USD
Average target price
141.6
USD
Spread / Average Target
+9.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.83% | 327B | |
| +29.99% | 682B | |
| +30.35% | 586B | |
| -3.75% | 364B | |
| +3.26% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +7.46% | 165B | |
| -1.86% | 161B |
- Stock Market
- Equities
- MRK Stock
- Funds and ETFs Merck & Co., Inc.